Welcome to the Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.

THE LATEST FROM THE MMRF
Previous
  • Michael Salmon NYC Marathon

    August 3, 2015

    We still have a few bibs for the world-renowned TCS NYC Marathon, 11/1/15. Register for
    the Team For Cures VIP Experience Here

  • Immuno Webinar 1 resized

    July 17, 2015

    Join Us for our Free 3-Part Immunotherapy Webinar Series. Register Today

  • MYMMRF

    July 16, 2015

    MyMMRF presents a Free Multiple Myeloma Patient Summit: Boston Aug. 22, 2015. Register Now

  • Kathy_minicarousel

    July 13, 2015

    Collaboration is the only way we do things at the MMRF. Kathy Giusti discusses in her ASCO Post, how the power of collaboration will help make precision medicine a reality.

    Read More

  • DNA_minicarousel

    July 12, 2015

    Read the second post in our blog series on immunotherapy: Boosting the Immune Response. Read More

  • MMRFChicago_20140921_246

    July 5, 2015

    Join Us in Chicago! 5K Walk/Run September 13th.
    Register Today

  • commungateway

    June 10, 2015

    Connect with patients, engage with experts, get the information you need! MMRF CoMMunity Gateway

Next

KNOWLEDGE LEADS TO CURES. Stay informed with our newsletter.

If you have multiple myeloma,
you have options.

At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.

LEARN MORE

We Are Beating Multiple Myeloma Now. Join Us.

Multiple myeloma patients have options today because the status quo just a few years ago was, to us, unacceptable.

The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in seven multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.

To improve the outcome, we partnered with
the best and rewrote the rules.

  • 2015
  • Revlimid® in combination with dexamethasone approved for newly diagnosed multiple myeloma patients
  • 2014
  • 10 clinical trials opened
  • 2014
  • CoMMpass Study enrollment almost completed
  • 2014
  • MMRC launches
    50th clinical trial
  • 2013
  • CoMMunity and Researcher Gateways launched
  • 2013
  • Pomalyst® approved
  • 2012
  • Kyprolis® approved
  • 2011
  • Record 8 treatments in
    Phase III trials
  • 2011
  • MMRF CoMMpassSM launched
  • 2008
  • Doxil approved
  • 2007
  • Revlimid® approved
  • 2006
  • Thalomid® approved
  • 2004
  • MMRC tissue bank established
  • 2004
  • MMRC founded
  • 2003
  • Velcade® approved
  • 2002
  • Zometa® approved
  • 1998
  • MMRF established

The MMRF changed the multiple myeloma treatment
landscape by removing obstacles and injecting speed at each step of
the research and drug development process.